Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB5613

Caption

A bill to improve the quality, appropriateness, and effectiveness of diagnosis in health care, and for other purposes.

Impact

If enacted, SB5613 will have substantial implications for state laws and healthcare practices by allocating significant federal funding—$20 million for the fiscal year 2023, increasing to $35 million annually by fiscal year 2027—towards improving diagnostic safety and quality. This funding aims to support innovative research that addresses existing knowledge gaps and challenges healthcare providers face in diagnostic practices. The establishment of an Interagency Council on Improving Diagnosis in Healthcare is also a key provision of the bill, intended to enhance coordination among federal agencies and address systemic barriers hindering research and implementation in this area.

Summary

SB5613, titled the 'Improving Diagnosis in Medicine Act of 2022', aims to enhance the quality, appropriateness, and effectiveness of diagnosis within the U.S. healthcare system. The bill proposes the establishment of a comprehensive research program focused on identifying and reducing diagnostic errors and delays, which can lead to significant patient harm. The program will support the development and dissemination of evidence-based strategies and best practices to improve the diagnostic process and patient outcomes. It emphasizes the importance of linking research directly with clinical practice through the establishment of Centers of Diagnostic Excellence across diverse geographical locations.

Contention

Notable points of contention surrounding SB5613 focus on the balance between federal oversight and local control in healthcare practices. While supporters argue that a structured federal approach will ensure consistent improvement in diagnostic practices and patient care, critics may raise concerns about potential bureaucratic inefficiencies and the ability of local healthcare entities to adapt the prescribed guidelines to meet specific community needs. Furthermore, the effectiveness of the proposed Centers of Diagnostic Excellence in actual clinical practice remains a critical discussion point, particularly regarding their operational autonomy and integration within established healthcare structures.

Companion Bills

No companion bills found.

Similar Bills

US HB10135

Improving Diagnosis in Medicine Act of 2024

US SB4246

Advancing Menopause Care and Mid-Life Women’s Health Act

US HR1514

Recognizing that cancer patients have the right to receive care that ensures effective prevention, early diagnosis, improved outcomes, optimal patient rehabilitation, and affordable health care.

US SB139

Advancing FASD Research, Services and Prevention Act or the FASD Respect ActThis bill reauthorizes and modifies programs that are administered by the Department of Health and Human Services (HHS) to address fetal alcohol spectrum disorders (FASD), including educational and research programs.The bill also establishes FASD Centers for Excellence to support FASD prevention, such as through screenings, public awareness campaigns, and trainings, particularly at the state and local levels.

US HR1356

Expressing support for the designation of October 9 through October 16, 2024, as "National Dyspraxia/Developmental Coordination Disorder (DCD) Awareness Week" and a commitment to raise awareness of dyspraxia/DCD in the United States.

US HB10297

Thyroid Disease CARE Act of 2024 Thyroid Disease Coverage, Awareness, Research, and Education Act of 2024

US SB755

Finn Sawyer Access to Cancer Testing Act This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer. Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

US SR590

A resolution designating March 15, 2024, as "Long COVID Awareness Day".